4//SEC Filing
Klearman Micki 4
Accession 0001209191-23-043443
CIK 0001645666other
Filed
Jul 25, 8:00 PM ET
Accepted
Jul 26, 5:08 PM ET
Size
16.6 KB
Accession
0001209191-23-043443
Insider Transaction Report
Form 4
Klearman Micki
Director
Transactions
- Award
Stock Option (Right to Buy)
2023-07-24+26,000→ 26,000 totalExercise: $2.28Exp: 2031-06-27→ Common Stock (26,000 underlying) - Award
Stock Option (Right to Buy)
2023-07-24+26,000→ 26,000 totalExercise: $2.28Exp: 2032-06-15→ Common Stock (26,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−52,000→ 0 totalExercise: $5.94Exp: 2031-05-31→ Common Stock (52,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−26,000→ 0 totalExercise: $5.59Exp: 2031-06-27→ Common Stock (26,000 underlying) - Award
Stock Option (Right to Buy)
2023-07-24+52,000→ 52,000 totalExercise: $2.28Exp: 2031-05-31→ Common Stock (52,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−26,000→ 0 totalExercise: $4.80Exp: 2032-06-15→ Common Stock (26,000 underlying)
Footnotes (3)
- [F1]One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis following the vesting commencement date of June 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
- [F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
- [F3]Fully vested and exercisable.
Documents
Issuer
Kezar Life Sciences, Inc.
CIK 0001645666
Entity typeother
Related Parties
1- filerCIK 0001864934
Filing Metadata
- Form type
- 4
- Filed
- Jul 25, 8:00 PM ET
- Accepted
- Jul 26, 5:08 PM ET
- Size
- 16.6 KB